Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2677-2687

  Ringe, J D ^a,e   Christodoulakos, G E ^b   Mellstrom D ^c   Petto, H ^d   Nickelsen, T ^d   Marin F ^d   Pavo, I ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Lilly Medical Research Center Europe   (United Kingdom)

^e Medical Department IV/General Internal Medicine   (Germany)

Author keywords

Bisphosphonates; Compliance; Discontinuation; Osteoporosis; Postmenopausal women; Raloxifene; Tolerability

Indexed keywords

ALENDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG WITHDRAWAL; EUROPEAN UNION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTOR;

ALENDRONATE; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE;

EID: 36348975143     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007X226357     Document Type: Article

References (34)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535-41
2. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral efficacy with risedronate therapy (VERT) study group]. J Am Med Assoc 1999;282:1344-52
4. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4
5. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003;14:965-8
6. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245-56
7. Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-8
8. Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynaecol Reprod Biol 1995;59:57-60
9. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282-9
10. Den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-12
11. Ettinger B, Tosteson AN, Grove M, et al. Side effect severity and discontinuation rate among women initiating hormone replacement therapy, raloxifene, or alendronate following BMD testing. Bone 2001;28:S76
12. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001;8:328-32
13. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
14. Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
15. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-9
16. Greendale GA, Wells B, Marcus R, et al. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000;160:3065-71
17. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
18. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis Int 2003;14:808-13
19. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
20. Brooks RG. EuroQoL - the current state of play. Health Policy 1996;37:53-72
21. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976;1:1265-8
22. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74
23. Dolan P. Modeling valuations for EuroQoL health states. Medical Care 1997;35:1095-1108
24. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003-8
25. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119:S18-S24
26. Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005;17:143-9
27. Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-51
28. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
29. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645-52
30. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-42
31. Rossini M, Bianchi G, Di Munno O, et al.; Treatment of Osteoporosis in clinical Practice (TOP) study group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 2006;17:914-21
32. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871-86
33. Mersfelder T, Armitstead JA, Ivey MF, Cedars M. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 1999;18:50-8
34. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 2006;119:S32-S37